Repligen Corp
Repligen Corp (RGEN) Covered Calls
As of September 24, 2026, RGEN has 71 covered call opportunities in the coming three months. Return ranges from 4.3 to 54.7% until expiration. Annualized return ranges from 18.4 to 477.9%. The nearest expiration is October 16, 2026. Maximum potential profit is $10,097.
Read more
Running RGEN covered calls helps you generate consistent income from Repligen Corp's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Repligen Corp involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best RGEN covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if RGEN stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling RGEN covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Repligen Corp covered call is worth writing.
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.
It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Income-focused investors, long-term RGEN holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling RGEN covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Repligen Corp covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryMedical Instruments & Supplies
- SectorHealthcare
- IV percentile69.05% Elevated
- Market cap (M$)10,759
- 52 weeks high0.91%
- 52 weeks low88.78%
- Analyst recommendationBuy
1.52 - Target price$189.00
-0.87% below the current stock price - Dividend—
- Payout ratio0.00%
- Earnings date2026-11-03
- P/E259.85
- Future P/E72.33
- EPS (ttm)0.73
- EPS growth next 5 years26.39%
As of September 24, 2026
| 2026-10-16 | 23 | 240.00 | 30.06 | 0.10 | 2.85 | 5557.00 | 30.11 | 477.90 | -0.05 | +0.10 | 12 | 2.75 |
| 2026-10-16 | 23 | 230.00 | 24.64 | 0.45 | 1.35 | 4592.00 | 24.88 | 394.91 | -0.24 | +0.08 | 10 | 0.90 |
| 2026-10-16 | 23 | 220.00 | 19.22 | 1.05 | 2.20 | 3652.00 | 19.79 | 314.07 | -0.57 | +0.13 | 55 | 1.15 |
| 2026-10-16 | 23 | 210.00 | 13.80 | 1.00 | 4.00 | 2647.00 | 14.34 | 227.64 | -0.54 | +0.19 | 29 | 3.00 |
| 2026-11-20 | 58 | 250.00 | 35.48 | 0.05 | 3.90 | 6552.00 | 35.51 | 223.45 | -0.03 | +0.11 | 1 | 3.85 |
| 2026-11-20 | 58 | 240.00 | 30.06 | 0.60 | 4.50 | 5607.00 | 30.39 | 191.22 | -0.33 | +0.14 | 3 | 3.90 |
| 2026-12-18 | 86 | 260.00 | 40.90 | 0.40 | 4.10 | 7587.00 | 41.12 | 174.50 | -0.22 | +0.11 | 8 | 3.70 |
| 2026-10-16 | 23 | 200.00 | 8.38 | 3.70 | 4.40 | 1917.00 | 10.39 | 164.86 | -2.01 | +0.29 | 3,116 | 0.70 |
| 2026-11-20 | 58 | 230.00 | 24.64 | 1.80 | 5.70 | 4727.00 | 25.62 | 161.21 | -0.98 | +0.19 | 6 | 3.90 |
| 2026-12-18 | 86 | 250.00 | 35.48 | 2.30 | 4.90 | 6777.00 | 36.73 | 155.87 | -1.25 | +0.16 | 8 | 2.60 |
As of September 24, 2026
Sell covered calls with the data behind you
Find the best RGEN covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→